India, Aug. 19 -- The Government of India issued the following news release:
The key outcomes and the details regarding companies, incentive outlays and domestic capacity added since inception are as follows:
PLI Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (also known as the PLI Scheme for Bulk Drugs): The objective of the scheme is to improve self-reliance and reduce import dependence in critical KSMs, DIs and APIs. The scheme has a total financial outlay of rs 6,940 crore. 32 companies/pharmaceutical entities have been selected for greenfield production through 48 projects involving 33 APIs/DIs/KSMs. Key outcomes...